about
The Potential Role of Kallistatin in the Development of Abdominal Aortic AneurysmNovel roles of kallistatin, a specific tissue kallikrein inhibitor, in vascular remodelingQuantitative mass spectrometry analysis using PAcIFIC for the identification of plasma diagnostic biomarkers for abdominal aortic aneurysmProteomic analysis reveals alterations in the renal kallikrein pathway during hypoxia-induced hypertensionKruppel-like factor 4 is a novel mediator of Kallistatin in inhibiting endothelial inflammation via increased endothelial nitric-oxide synthase expression.Plasma kallistatin in critically ill patients with severe sepsis and septic shock.Identification of a major heparin-binding site in kallistatin.Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activationExploring the human plasma proteome for humoral mediators of remote ischemic preconditioning--a word of caution.Localization and expression of tissue kallikrein and kallistatin in human blood vessels.The kallikrein-kinin system in humans.Thyroid hormone and COUP-TF1 regulate kallikrein-binding protein (KBP) gene expression.Novel role of kallistatin in vascular repair by promoting mobility, viability, and function of endothelial progenitor cells.The plasma proteomic signature as a strategic tool for early diagnosis of acute coronary syndromeKallistatin ameliorates influenza virus pathogenesis by inhibition of kallikrein-related peptidase 1-mediated cleavage of viral hemagglutininKallikrein-kinin in stroke, cardiovascular and renal disease.The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction.Nafamostat mesilate promotes endothelium-dependent vasorelaxation via the Akt-eNOS dependent pathwayKallistatin modulates immune cells and confers anti-inflammatory response to protect mice from group A streptococcal infection.Antiangiogenic and antineuroinflammatory effects of kallistatin through interactions with the canonical Wnt pathway.Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing.A Novel Category of Anti-Hypertensive Drugs for Treating Salt-Sensitive Hypertension on the Basis of a New Development ConceptThe platelet receptor GPVI mediates both adhesion and signaling responses to collagen in a receptor density-dependent fashion.Increased serum kallistatin levels in type 1 diabetes patients with vascular complicationsKallistatin levels in HIV-infected patients and effects of statin therapy.Protective Role of Kallistatin in Vascular and Organ Injury.SERPINA3K induces apoptosis in human colorectal cancer cells via activating the Fas/FasL/caspase-8 signaling pathway.Vasodilator and antihypertensive effects of a novel N-acylhydrazone derivative mediated by the inhibition of L-type Ca²⁺ channels.Evidence of zeta protein kinase C involvement in polymorphonuclear neutrophil integrin-dependent adhesion and chemotaxis.Role of kallistatin in prevention of cardiac remodeling after chronic myocardial infarction.Kallistatin inhibits lymphangiogenesis and lymphatic metastasis of gastric cancer by downregulating VEGF-C expression and secretion.Opposing Effects of Oxygen Regulation on Kallistatin Expression: Kallistatin as a Novel Mediator of Oxygen-Induced HIF-1-eNOS-NO Pathway.Codon optimization increases human kallistatin expression in Escherichia coli.
P2860
Q26741231-5AC95BB5-1B09-4819-B4B9-5861AF40B37EQ28205487-C2B25E2E-C00A-49B5-B41F-DDC1A05E5DF2Q28478305-59FB036E-423F-48F7-A16C-A1E482DD0307Q28575648-9A8D613A-BDF8-4525-81B9-9BC60F7F069AQ33512668-F92212AB-5971-4081-A898-7E60C59C2C98Q33725117-88DF4A07-9D8A-4999-9F16-4D7BCAF6719EQ33920033-00B05411-966D-4371-A513-A396CA9A715DQ34070667-50FF55BA-B35A-4DF5-B1B6-96F73A22387BQ34343547-E92DFF19-1788-4315-BCD7-D516C8C8A32BQ34487686-A1A9EF75-FA70-414A-A642-1DC9CB367B90Q34570447-DB83F818-49CA-421E-AA01-DF925FB49A9DQ34578472-EFB56AAA-E6D1-46C2-B5D2-2A8EAB9F7CBCQ35070827-DBAFE3E4-9050-4A7F-A8A5-150A6CF5356CQ35673497-7CE8F503-4DBE-40F3-88AE-AF06B040E36BQ35960792-3FABA3BF-0A01-4130-8341-B955C4BAB1E3Q36011348-A0F2935A-E9AF-4B8B-B8ED-878F3862577BQ36519364-62AA2EC7-601D-4DB7-86FD-268066CB5DF5Q37239802-3009C8CC-4FDB-47F4-A393-C0C0D3A61621Q37263454-07BD8448-55F4-4E2B-B98A-681E082D3AC9Q37333523-4A24EB5C-3E82-45F3-A98D-E2AA703F0536Q37697813-19039DC1-3FEC-43EB-AABC-0312AE294EC4Q37709440-C6730B7B-6FB6-4310-ACAA-6DBF760D0BDAQ40766523-3253F2D6-690E-4F83-A3E6-989D8E0B6D5EQ42034969-C5AF0E2D-4A65-4EF9-A961-AA2C1FF479EAQ42101794-485FC5B4-720F-4F74-8885-214D63C6C529Q42360588-E020A673-49E5-4234-B422-DE665525BE2AQ44088705-E00D28FF-D011-416E-B04D-A9BB3673E6D3Q45722561-1C0EE51E-030D-4BC0-9FD9-9FCEB56BC230Q46277544-5BCD68C6-7658-4DF5-9691-A42DE3E5CE56Q46397663-2076B42A-2EFB-4994-8D1E-A750D6EAAEF2Q47247582-C5509A5F-5AB4-4A5A-B588-FE2C3050875AQ48129770-BA90D72C-8C80-466A-BEF9-36DFA2F1D97DQ50238802-E67D13F7-F255-432E-84B9-9945D0F3E061
P2860
description
1997 nî lūn-bûn
@nan
1997 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Kallistatin is a potent new vasodilator
@ast
Kallistatin is a potent new vasodilator
@en
Kallistatin is a potent new vasodilator
@nl
type
label
Kallistatin is a potent new vasodilator
@ast
Kallistatin is a potent new vasodilator
@en
Kallistatin is a potent new vasodilator
@nl
prefLabel
Kallistatin is a potent new vasodilator
@ast
Kallistatin is a potent new vasodilator
@en
Kallistatin is a potent new vasodilator
@nl
P2093
P2860
P3181
P356
P1476
Kallistatin is a potent new vasodilator
@en
P2093
P2860
P3181
P356
10.1172/JCI119502
P407
P577
1997-07-01T00:00:00Z